| Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia (NCT05601466) | Institute of Hematology & Blood Diseases Hospital, China | 2022-03-26 |
| Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML (NCT05177731) | Chen Suning | 2022-03-01 |
| Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS (NCT04749355) | BioSight Ltd. | 2021-11-14 |
| A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) (NCT04964518) | Ascentage Pharma Group Inc. | 2021-07-30 |
| Precision Therapy Versus Standard Therapy in AML and MDS in Elderly (NCT05025098) | University Hospital, Akershus | 2021-06-22 |
| A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) (NCT04755244) | ALX Oncology Inc. | 2021-05-05 |
| Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia (NCT04512105) | University of California, Irvine | 2020-12-02 |
| FT538 in Subjects With Advanced Hematologic Malignancies (NCT04614636) | Fate Therapeutics | 2020-10-17 |
| NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS (NCT04623944) | Nkarta, Inc. | 2020-09-21 |
| Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS (NCT04482894) | University of Virginia | 2020-08-19 |
| Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia. (NCT04425655) | University of California, San Diego | 2020-08-05 |
| HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt. (NCT04496999) | Insel Gruppe AG, University Hospital Bern | 2020-07-13 |
| Quality of Life Model for Older Patients With AML (NCT04380441) | H. Lee Moffitt Cancer Center and Research Institute | 2020-07-08 |
| Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia (NCT04128020) | Sherif Farag | 2019-10-10 |
| Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib (NCT04079738) | H Scott Boswell | 2019-09-20 |
| A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS (NCT03884829) | Cyclacel Pharmaceuticals, Inc. | 2019-03-25 |
| EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 (NCT03612739) | Celyad Oncology SA | 2018-12-01 |
| Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia (NCT02986620) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2017-10-31 |
| Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT03194685) | Fujifilm Pharmaceuticals U.S.A., Inc. | 2017-05-05 |